Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
The series of the cardiovascular outcome trails have demonstrated the nephroprotective properties of the gliflozins. Canagliflozin in the CREDENCE, which was the first study with a primary focus on the evaluation of the nephroprotective properties of gliflozin, have demonstrated the possibility to s...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Endocrinology Research Centre
2022-02-01
|
| Col·lecció: | Сахарный диабет |
| Matèries: | |
| Accés en línia: | https://www.dia-endojournals.ru/jour/article/view/12864 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|